Skip to main content Skip to section navigation Skip to footer
chevron_leftBack to www.corbuspharma.com
Corbus Pharmaceuticals Holdings, Inc. IR Overview
  • Investors
  • Presentations
  • Analyst Coverage
  • News / Events
    • Press Releases
    • Events
  • Company Information
    • Profile
    • IR Contacts
    • FAQ
  • Financial Information
    • Financial Results
  • Stock Data
    • Quote and Chart
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • chevron_leftBack to www.corbuspharma.com

Press Releases

News / Events

News / Events

  • Press Releases
  • Events
Feb 2, 2024 • 4:01 pm EST
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jan 31, 2024 • 9:19 am EST
Corbus Pharmaceuticals Announces Pricing of Public Offering
Jan 30, 2024 • 6:55 pm EST
Corbus Pharmaceuticals Announces Proposed Public Offering
Jan 26, 2024 • 7:30 am EST
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
Jan 23, 2024 • 8:00 am EST
Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
Jan 9, 2024 • 8:00 am EST
Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
Dec 18, 2023 • 8:00 am EST
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
Nov 7, 2023 • 8:00 am EST
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 2, 2023 • 8:00 am EDT
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Oct 17, 2023 • 8:00 am EDT
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 29
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
©2025 Corbus Pharmaceuticals Holdings, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement